Alzheimer's Blood Test Is a Step Closer to the Clinic

Researchers from Washington University School of Medicine in St. Louis report that they can measure levels of the Alzheimer’s protein amyloid beta in the blood and use such levels to predict whether the protein has accumulated in the brain. When blood amyloid levels are combined with two other major Alzheimer’s risk factors – age and the presence of the genetic variant APOE4 – people with early Alzheimer’s brain changes can be identified with 94% accuracy, the study found. The findings, published Aug. 1 in the journal Neurology, represent another step toward a blood test to identify people on track to develop Alzheimer’s before symptoms arise. Surprisingly, the test may be even more sensitive than the gold standard – a PET brain scan – at detecting the beginnings of amyloid deposition in the brain. Such a test may become available at doctors’ offices within a few years, but its benefits will be much greater once there are treatments to halt the disease process and forestall dementia. Clinical trials of preventive drug candidates have been hampered by the difficulty of identifying participants who have Alzheimer’s brain changes but no cognitive problems. The blood test could provide a way to efficiently screen for people with early signs of disease so they can participate in clinical trials evaluating whether drugs can prevent Alzheimer’s dementia. https://www.technologynetworks.com/neuroscience/news/alzheimers-blood-test-is-a-step-closer-to-the-clinic-322477?utm_campaign=NEWSLETTER_TN_Breaking%20Science%20News&utm_source=hs_email&utm_medium=email&utm_content=75348710&_hsenc=p2ANqtz-_-glcYMZ3G2fX8SFfv82Q5kJcamjEtIMA8BUDPAmSvO2HlvpELoPnqh_RmlzTo78X6g52XvFhwkyUi6JMFX3FcGBFLYQ&_hsmi=75348710